Abstract
It is clear from the studies summarized above that the combination of leucovorin and 5-FU can salvage 15–20% of heavily-pretreated patients with advanced breast cancer. In previously-untreated patients, the combination generates objective responses in over one third of women with a very modest and acceptable toxicity profile. It is also clear that the addition of mitoxantrone or cisplatin to 5-FU and leucovorin produces very effective regimens, that, at least in the case of the platinum combination, may be quite active in patients who have failed therapy with an anthracycline. All of these recently-completed trials, suggest that studies currently in progress aimed at improving the biochemical modulation of the fluoropyrimidines have real promise for enhancing the therapy of patients with advanced breast cancer further.
This study was supported by Cancer Center Support Grant CA-33572. Requests for reprints should be addressed to James H. Doroshow, M.D., Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA 91010. These results have been reported, in part, in Proc. Amer. Soc. Clin. Oncol, 10: 65 (1991).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Henderson IC, Hayes DF, Come S, et al: New agents and new medical treatments for advanced breast cancer. Semin Oncol 14: 34–64, 1987
Ansfield FJ, Ramirez G, Mackman S, et al: A ten-year study of 5-fluorouracil in disseminated breast cancer with clinical results and survival times. Cancer Res 29: 1062–1066, 1969
Huan S, Padzur R, Singhakowinta A, et al: Low-dose continuous infusion 5-fluorouracil: evaluation in advanced breast carcinoma. Cancer 63: 419–422, 1989
Marini G, Simoncini E, Zaniboni A, et al: 5-Fluorouracil and high-dose folinic acid as salvage treatment of advanced breast cancer: an update. Oncology 44: 336–340, 1987
Doroshow JH, Leong L, Margolin K, et al: Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium. J Clin Oncol 7: 439–444, 1989
Swain SM, Lippman ME, Egan EF, et al: Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 890–899, 1989
Loprinzi CL, Ingle JN, Schaid DJ, et al: 5-Fluorouracil plus leucovorin in women with metastatic breast cancer. Am J Clin Oncol 14: 30–32, 1991
Margolin K, Doroshow J, Green S, et al: Treatment of advanced breast cancer with 5-FU and high-dose folinic acid. Proc Amer Soc Clin Oncol 10: 59, 1991 (abstr)
Margolin KA, Doroshow JH, Akman SA, et al: Effective initial therapy of advanced breast cancer with fluorouracil and high-dose, continuous infusion calcium leucovorin. J Clin Oncol 10: 1278–1283, 1992
Fine S, Erlichman C, Kaizer L, et al: Phase II trial of 5FU + folinic acid (FA) as first line treatment for metastatic breast cancer. Proc Amer Soc Clin Oncol 7: 41, 1988 (abstr)
Cowan JD, Neidhart J, McClure S, et al: Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. J Natl Cancer Inst 83: 1077–1084, 1991
Ellis GK, Green S, Schulman S, et al: Alternating weekly doxorubicin and 5-fluorouracil/leucovorin followed by weekly doxorubicin and daily cyclophosphamide in stage IV breast cancer. A Southwest Oncology Group study. Cancer 68: 934–939, 1991
Palmeri S, Gebbia V, Russo A, et al: Cyclophosphamide plus epidoxorubicin and 5-fluorouracil with folinic acid as a novel treatment in metastatic breast cancer: preliminary results of a phase II study. J Chemother 3: 176–179, 1991
Hainsworth JD, Andrews MB, Johnson DH, et al: Mitoxantrone, fluorouracil, and high-dose leucovorin: an effective, well-tolerated regimen for metastatic breast cancer. J Clin Oncol 9: 1731–1735, 1991
Jones SE, Mennel RG, Brooks B, et al: Phase II study of mitoxantrone, leucovorin, and infusional fluorouracil for treatment of metastatic breast cancer. J Clin Oncol 9: 1736–1739, 1991
Ardalan B, Sridhar KS, Benedetto P, et al: A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. Cancer 68: 1242–1246, 1991
Bhalla K, Birkhofer M, Bhalla M, et al: A phase I study of a combination of allopurinol, 5-fluorouracil and leucovorin followed by hydroxyurea in patients with advanced gastrointestinal and breast cancer. Am J Clin Oncol 14: 509–513, 1991
Pronzato P, Amoroso D, Ardizzoni A, et al: Sequential administration of cyclophosphamide, methotrexate, 5-fluorouracil, and folinic acid as salvage treatment in metastatic breast cancer. Am J Clin Oncol 10: 404–406, 1987
Leong L, Doroshow J, Akman S, et al: Phase II trial of 5-fluorouracil (5-FU), folinic acid (FA), and cis-platinum (CDDP) in metastatic breast cancer. Proc Amer Soc Clin Oncol 10: 65, 1991 (abstr)
Sledge GW, Jr., Loehrer PJ, Sr., Roth BJ, et al: Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 6: 1811–1814, 1988
Allegra CJ, Mayer A, Reed E, et al: Therapy of patients with metastatic breast cancer (MBC) with 5-fluorouracil (FU), leucovorin (L), and carboplatin (CBDCA). Proc Amer Soc Clin Oncol 8: 54, 1989 (abstr)
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Doroshow, J.H. et al. (1993). Fluorouracil and Leucovorin in Advanced Breast Cancer. In: Rustum, Y.M. (eds) Novel Approaches to Selective Treatments of Human Solid Tumors. Advances in Experimental Medicine and Biology, vol 339. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2488-5_19
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2488-5_19
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6060-5
Online ISBN: 978-1-4615-2488-5
eBook Packages: Springer Book Archive